Experience of Anti-Viral Therapy in Hepatitis B-Associated Membranous Nephropathy, Including Lamivudine-Resistant Strains |
Sun, In O
(Division of Nephrology, Department of Internal Medicine, The Catholic University of Korea College of Medicine)
Hong, Yu Ah (Division of Nephrology, Department of Internal Medicine, The Catholic University of Korea College of Medicine) Park, Hoon Suk (Division of Nephrology, Department of Internal Medicine, The Catholic University of Korea College of Medicine) Choi, Sun Ryoung (Division of Nephrology, Department of Internal Medicine, The Catholic University of Korea College of Medicine) Chung, Byung Ha (Division of Nephrology, Department of Internal Medicine, The Catholic University of Korea College of Medicine) Park, Cheol Whee (Division of Nephrology, Department of Internal Medicine, The Catholic University of Korea College of Medicine) Yang, Chul Woo (Division of Nephrology, Department of Internal Medicine, The Catholic University of Korea College of Medicine) Kim, Yong Soo (Division of Nephrology, Department of Internal Medicine, The Catholic University of Korea College of Medicine) Choi, Bum Soon (Division of Nephrology, Department of Internal Medicine, The Catholic University of Korea College of Medicine) |
1 | Jefferson JA, Couser WG. Therapy of membranous nephropathy associated with malignancy and secondary causes. Semin Nephrol 2003;23:400-405. DOI ScienceOn |
2 | Zeng CH, Chen HM, Wang RS, et al. Etiology and clinical characteristics of membranous nephropathy in Chinese patients. Am J Kidney Dis 2008;52:691-698. DOI ScienceOn |
3 | Lee EJ, Lee SH, Won JJ, et al. Etiology and clinical course of secondary membranous nephropathy. Korean J Med 2005;68:407-416. |
4 | Lai KN, Li PK, Lui SF, et al. Membranous nephropathy related to hepatitis B virus in adults. N Engl J Med 1991;324:1457-1463. DOI ScienceOn |
5 | Lai KN, Tam JS, Lin HJ, Lai FM. The therapeutic dilemma of the usage of corticosteroid in patients with membranous nephropathy and persistent hepatitis B virus surface antigenaemia. Nephron 1990;54:12-17. DOI |
6 | Conjeevaram HS, Hoofnagle JH, Austin HA, Park Y, Fried MW, Di Bisceglie AM. Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alfa. Gastroenterology 1995;109:540-546. DOI ScienceOn |
7 | Tang S, Lai FM, Lui YH, et al. Lamivudine in hepatitis B-associated membranous nephropathy. Kidney Int 2005;68:1750-1758. DOI ScienceOn |
8 | Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B:Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000;119:172-180. DOI ScienceOn |
9 | Allen MI, Gauthier J, DesLauriers M, et al. Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine. J Clin Microbiol 1999;37:3338-3347. |
10 | Cattran DC, Appel GB, Hebert LA, et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int 2001;59:1484-1490. DOI ScienceOn |
11 | Yuen MF, Lai CL. Treatment of chronic hepatitis B: evolution over two decades. J Gastroenterol Hepatol 2011;26 Suppl 1:138-143. DOI |
12 | Yi Z, Jie YW, Nan Z. The efficacy of anti-viral therapy on hepatitis B virus-associated glomerulonephritis: a systematic review and meta-analysis. Ann Hepatol 2011;10:165-173. |
13 | Lau DT, Khokhar MF, Doo E, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000;32:828-834. DOI ScienceOn |
14 | Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-539. DOI ScienceOn |
15 | Fu L, Liu SH, Cheng YC. Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues. Biochem Pharmacol 1999;57:1351-1359. DOI ScienceOn |
16 | Tak WY, Park SY, Cho CM, et al. Clinical, biochemical, and pathological characteristics of clevudine-associated myopathy. J Hepatol 2010;53:261-266. DOI ScienceOn |
17 | Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-1010. DOI ScienceOn |
18 | Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503-1514. DOI ScienceOn |
19 | Ikee R, Ishioka K, Oka M, et al. Hepatitis B virus-related membranous nephropathy treated with entecavir. Nephrology (Carlton) 2010;15:266. |
20 | Lai AS, Lai KN. Viral nephropathy. Nat Clin Pract Nephrol 2006;2:254-262. |
21 | Johnson RJ, Couser WG. Hepatitis B infection and renal disease: clinical, immunopathogenetic and therapeutic considerations. Kidney Int 1990;37:663-676. DOI ScienceOn |
![]() |